CARGO Therapeutics, Inc.

CRGX

Offer Price Offer Size 3-Year Outlook Volatility 1st Day Turnover
$15.00 18,800,000 Positive High 5.91%

Offering Team

Deal Managers

  • J P Morgan Chase
  • Jefferies
  • Truist Securities

Lawyers

  • Latham & Watkins LLP

Auditors

  • Deloitte & Touche LLP

Pre-IPO Investors

Investors

  • Google Ventures
  • Intel Ventures
  • Patricoff Ventures
  • Kleiner Perkins

Pre-IPO Holdings(%)

  • 30
  • 20
  • 05
  • 18

Deal Highlights

We are a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients. Our programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. A CAR is a protein that has been engineered to modify T cells so they can recognize and destroy cancer cells. We believe the limitations of approved thera More

Deal Tracker

Investors

Filing

09 Nov, 2023

Offer

10 Nov, 2023

Look Ahead

Lock Up Expiry

10 May, 2024

Earning

Nov 1, 2018

IPO Terms

Offer Price $15.00
Offer Size 18M

Market Sentiments

Stock Price